NEWTOWN SQUARE, Pa., April 11, 2019 /PRNewswire/ -- This Press Release is specifically targeted for medical and scientific professionals and not intended towards consumers.
Kibow Biotech, Inc. is proud to present its recent findings, "Removal of Urea by Specific Probiotic Strain (KB19) in Chronic Kidney Disease Patients" (https://isnwcn2019.org/), during the poster presentation session at The World Congress of Nephrology (WCN) in Australia, April 12-15, 2019.
We are proud to be presenting our latest abstract which combines over 20 years of research while supporting of our company's core business principal: modulation of gut microbiome using pro and prebiotics, for various health conditions.
"Urea, a marker of uraemic retention in chronic kidney disease (CKD), has traditionally been considered to be biologically inert. However, a number of recent experimental data suggest that urea is toxic at concentrations representative for CKD." 1.
Even in healthy individuals, high blood urea is associated with a higher risk of developing incident diabetes along with risks of cardiovascular impacts. In CKD patients urea degrades to cyanate, a toxic metabolite. In turn, cyanate binds to serum albumin and other proteins creating carbamylated proteins. The carbamylated compounds increase mortality risks in CKD patients and accelerate the progression of CKD. The urea in CKD patients also disrupts the protective intestinal barrier leading to inflammation and a leaky gut.
Dr. Natarajan Ranganathan, the chief R&D scientist and architect of "Enteric Dialysis", emphasized the importance of targeting urea accumulation alongside several other uremic toxins in CKD populations/patients. It is therefore important to address "UREA REMOVAL" in CKD applications.
Our R&D labs are able to document that our highly specific probiotic strain, S. thermophilus KB19, has the highest urea removal capabilities of 55 - 65% in our product, RENADYLTM. For comparison, other products sold commercially in USA, India, and other overseas market, demonstrate a very low removal of urea at only 0 - 15%. The details of this abstract and poster can be found with all other 55 abstracts published by the company since 2002 at https://kibowbiotech.com/rd/. The 16 peer reviewed journal publications of Kibow's scientific R&D since 2005 can also be accessed at https://kibowbiotech.com/journal-publications/
About Kibow Biotech: Founded October 1, 1997, in Philadelphia, Kibow Biotech specializes in research, development, and commercialization of patented and proprietary probiotic healthcare supplements. The Company's primary mission is to offer affordable, readily available and easily administered healthcare supplements in support of kidney health and other healthcare applications. The Company's flagship product, RENADYL™, is currently marketed in the U.S.A., Canada, India, Mexico, Malaysia, and will progressively be made available worldwide, according to individual countries' governmental rules and regulatory authorities.
The company's extensive scientific (R&D) and clinical data from three different pilot/observational scientific human clinical trials have been published in peer-reviewed scientific /medical journals and can be found at (http://www.kibowbiotech.com/rd/).
About Uremic Toxin Reduction Technology – also known as "Enteric Dialysis®": Kibow's novel "uremic toxin removal technology" addresses the diffusion of various uremic toxins into the bowel as a consequence of failing kidney function. The Company's patented and proprietary dietary supplements, Renadyl™, for humans, and Azodyl®, a veterinary formulation licensed to Vetoquinol for cats and dogs (http://www.vetoquinolusa.com/), with moderate to severe kidney failure consists of a combination of three specific probiotic microbial strains and chosen prebiotics.
The information in this press release contains forward-looking statements regarding future events, including statements about the clinical and therapeutic potential of Kibow Biotech's products. Certain forward-looking statements may be identified by reference to a future period or by use of forward-looking terminology such as "may" and "potential." Kibow intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except as required by law, Kibow Biotech assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
⃰ These statements have not been evaluated by the US Food and Drug Administration.
These products are not intended to diagnose, treat, cure or to prevent any disease.
1. Urea and chronic kidney disease: the comeback of the century?; Raymond Vanholder, Tessa Gryp, and Griet Glorieux, Nephrology Dialysis Transplantation (2018) 33:4-12
For further information, contact:
Terrence O. Tormey, CEO
+1 (610) 353-5130
SOURCE Kibow Biotech, Inc.